ProfileGDS5678 / 1426782_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 71% 73% 71% 71% 70% 73% 76% 79% 72% 72% 73% 71% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5458272
GSM967853U87-EV human glioblastoma xenograft - Control 24.5312671
GSM967854U87-EV human glioblastoma xenograft - Control 34.6974273
GSM967855U87-EV human glioblastoma xenograft - Control 44.5814671
GSM967856U87-EV human glioblastoma xenograft - Control 54.4868471
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3114670
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6037373
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.1135676
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4564779
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6296272
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5599672
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7962973
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5164571
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7100573